乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASCO

<乌鸦传媒>Obamacare Cut Racial Disparities in Cancer Care

Time to cancer treatment evens in blacks and whites with Medicaid expansion

<乌鸦传媒>Trials Back Earlier Use of Androgen Receptor Inhibitors

Improved survival in metastatic hormone-sensitive prostate cancer

<乌鸦传媒>Add-On Metformin Disappoints in Metastatic CRPC

No meaningful clinical benefit when paired with docetaxel-prednisone in castration-resistant prostate cancer

<乌鸦传媒>POLO Will Change Practice in Pancreatic Cancer

"Huge step forward" for metastatic disease, says expert

<乌鸦传媒>Dramatic OS Boost With Kisqali in Young Breast Ca Patients

'First study to demonstrate improved survival for a targeted therapy' in advanced disease

<乌鸦传媒>Front-Line Keytruda: The New Standard in Gastric Ca Tx?

Pembrolizumab leads to comparable survival outcomes versus chemo

<乌鸦传媒>Low-Dose Tx Wins in Older Gastroesophageal Ca Patients

Overall survival maintained with gains in quality of life

<乌鸦传媒>Ditching Chemo Appears Viable in Frontline Follicular Lymphoma

PFS 'nearly identical' at 3 years with novel immunomodulatory combination

<乌鸦传媒>PFS Rises in Ovarian Ca with Repeat Bevacizumab

Magnitude of benefit similar to first-line therapy

<乌鸦传媒>Quick Intervention Improves Care in Geriatric Cancer Patients

Randomized trial improved oncologist-patient communication

<乌鸦传媒>Less Morbidity, Lower Costs Tied to MIS in Cervical Cancer

But minimally invasive surgery also linked to decreased survival

<乌鸦传媒>IMPACT Trial: Support for Targeted Cancer Tx Approaches

Survival doubled with therapy matched to tumor genetics

<乌鸦传媒>Pancreatic Ca Gets 20-Month Survival Boost

Aggressive post-surgery chemo regimen touted as new standard of care

<乌鸦传媒>Pre-Surgical CRT May Boost Survival in Pancreatic Ca

Further data needed to clarify best approach and who would benefit most

<乌鸦传媒>Many with Metastatic Kidney Cancer Can Skip Surgery

Overall survival with single-agent sunitinib better than with resection

<乌鸦传媒>Hot Chemo Fails in Rare Cancer

HIPEC and surgery equals surgery alone in peritoneal carcinomatosis

<乌鸦传媒>Rare Childhood Cancer Gets First Tx Advance in 30 Years

But impact unclear for U.S. rhabdomyosarcoma patients

<乌鸦传媒>Keytruda Alone Bests Chemo in Advanced NSCLC

Monotherapy boosts survival in patients with low PD-L1, no EGFR or ALK alterations

<乌鸦传媒>Ivosidenib Induces Deep Remissions in IDH1-Mutant AML

On strength of phase I data, drug appears headed for FDA approval

<乌鸦传媒>PI3K Inhibitor Has Mixed Results in Advanced Breast Cancer

Modest progression benefit, but substantial side effects, with taselisib

<乌鸦传媒>Women Get Less Aggressive Tx for Head and Neck Ca

Registry data find that women are less likely to receive chemotherapy or radiation than men

<乌鸦传媒>Lung Cancer Screening Rates Disappoint

Evidence shows benefit for high-risk smokers but few get tested

<乌鸦传媒>CBT Tops Acupuncture for Treating Insomnia in Cancer Survivors

But both methods provide alternative to sleeping pills

<乌鸦传媒>Six Months of Trastuzumab Equal to 12 in Breast Ca

Similar outcomes and less cardiotoxicity, but more research needed

<乌鸦传媒>Another CDK4/6 Inhibitor Boosts PFS in Breast Cancer

Abemaciclib-fulvestrant combo for advanced HR+/HER2- disease

<乌鸦传媒>No Survival Benefit with Node Dissection in Ovarian Ca

Macroscopic complete resection drives outcomes

<乌鸦传媒>Two Anti-HER2 Drugs Slightly Better Than One

Patient selection key to addition of pertuzumab to trastuzumab

<乌鸦传媒>New Standard for ALK-Positive NSCLC

Dramatic PFS, CNS benefits with alectinib

<乌鸦传媒>Genomic Testing Helps Cancer Patients -- When Results are Used

Also, liquid biopsy can ID drug-responsive tumors

<乌鸦传媒>Dacomitinib Sets PFS Record in Phase III NSCLC Trial

Next-gen EGFR inhibitor wins head-to-head battle with gefitinib, at least for efficacy

<乌鸦传媒>CAR T Cells Drive Outcomes in MM

Studies show promise for precision immunotherapy

<乌鸦传媒>Immunotherapy Shows Promise in Tough-to-Treat Mesothelioma

Outcomes improved with nivolumab alone or with ipilimumab in pretreated patients

<乌鸦传媒>Advanced Ca Patients Benefit from Online Symptom Reports

Patient-reported outcomes tied to increased survival

<乌鸦传媒>Trastuzumab Copycat Has Similar Efficacy

Phase III trial compared substances in early-stage breast cancer

<乌鸦传媒>Big Win for PARP Inhibitor in Breast Cancer

PFS boost for HER2-negative, BRCA-mutated disease

<乌鸦传媒>Short-Course RT Helps Retain Ability to Walk in Advanced Ca

Preferable to multi-dose radiotherapy for spinal cord compression

<乌鸦传媒>Novel Agent Shows Antitumor Activity in TRK-Fusion Cancers

Tumor genetics define treatment approach in early-stage trials

<乌鸦传媒>Mixed Results with Novel Tx in Sarcoma

Aldodoxorubicin can't boost PFS, but promising in L-sarcomas

<乌鸦传媒>Abiraterone Combo: A New Care Standard in Prostate Cancer?

Earlier treatment appears to improve survival in metastatic disease

<乌鸦传媒>Second Surgery Slows Recurrent Ovarian Cancer

But no survival gain seen in interim analysis of DESKTOP III

4